News

Filter

Added benefit for non-pre-treated Yervoy patients in advanced melanoma not proven, says IQWiG

Added benefit for non-pre-treated Yervoy patients in advanced melanoma not proven, says IQWiG

19-03-2014

The German Institute for Quality and Efficiency in Health Care (IQWiG) has re-assessed the added benefit…

Bristol-Myers SquibbGermanyNorthern EuropeOncologyPharmaceuticalPricingRegulationYervoy

COMPANY SPOTLIGHT

Menarini

Back to top